Securities Litigation
Datavault AI Files Defamation Lawsuit Against Wolfpack Research Over Short Report
Datavault AI has filed a defamation lawsuit against Wolfpack Research and its founder Dan David, alleging false claims in a short report caused significant harm to the company and its shareholders.
Datavault AI Condemns Wolfpack Research Short Report and Announces Legal Action
Datavault AI is pursuing legal action against Wolfpack Research for what it calls a false and defamatory short report while reaffirming its strong intellectual property position and growth strategy.
Quantum BioPharma Completes Warrant Expiration, Confirms CVR Distribution Date for Potential Litigation Windfall
Quantum BioPharma has finalized the expiration of hedge fund warrants and confirmed the record date for contingent value rights that could provide shareholders with a significant share of potential proceeds from its $700 million litigation.
Datavault AI Files Federal Lawsuit Alleging Market Manipulation and Defamation
Datavault AI has filed a federal lawsuit alleging securities fraud, defamation, and market manipulation through naked short selling and online misinformation campaigns targeting the company's stock.
Quantum BioPharma Launches $7 Million Whistleblower Program Targeting Stock Manipulation
Quantum BioPharma has implemented a public whistleblower policy offering up to $7 million for verifiable evidence of stock manipulation, demonstrating the company's commitment to market integrity amid ongoing legal proceedings.
Quantum BioPharma Ltd. Challenges Motion to Dismiss in $700 Million Market Manipulation Case
Quantum BioPharma Ltd. opposes a motion to dismiss in a significant lawsuit alleging market manipulation by major financial institutions, highlighting the potential implications for securities law enforcement and investor protection.
Datavault AI Inc. Files Lawsuit Alleging Securities Fraud and Defamation
Datavault AI Inc. (NASDAQ: DVLT) has launched a federal lawsuit alleging securities fraud and defamation related to 'naked' short selling and online misinformation, highlighting the challenges companies face in protecting their stock value and reputation.
Quantum BioPharma Ltd. Announces Special Dividend Linked to Litigation Proceeds
Quantum BioPharma Ltd. (NASDAQ: QNTM) plans to issue a special dividend in the form of Contingent Value Rights (CVRs) to its Class B Subordinate Voting Shareholders, tied to the outcome of a $700 million+ litigation against several banks for alleged stock manipulation.
Quantum BioPharma Files $700M Market Manipulation Lawsuit Against Financial Institutions
Quantum BioPharma has initiated a significant legal action against multiple financial institutions, alleging securities law violations through market manipulation tactics between 2020 and 2024, seeking substantial damages.